Ruxolitinib (S enantiomer) [941685-37-6]
Referencia HY-50856A-100mg
embalaje : 100mg
Marca : MedChemExpress
Ruxolitinib (S enantiomer) (S-Ruxolitinib) is the S-enantiomer of Ruxolitinib (HY-50856). Ruxolitinib (S enantiomer) is an orally active, potent JAK inhibitor.
Para uso exclusivo en investigación. No vendemos a pacientes.
Ruxolitinib (S enantiomer) Estructura química
No. CAS : 941685-37-6
This product is a controlled substance and not for sale in your territory.
Based on 4 publication(s) in Google Scholar
Other Forms of Ruxolitinib (S enantiomer):
- Ruxolitinib In-stock
- Ruxolitinib phosphate In-stock
- Ruxolitinib sulfate Obtener un presupuesto
- (Rac)-Ruxolitinib-d9 Obtener un presupuesto
Ver todos los productos específicos de isoformas JAK:
Descripciòn |
Ruxolitinib (S enantiomer) (S-Ruxolitinib) is the S-enantiomer of Ruxolitinib (HY-50856). Ruxolitinib (S enantiomer) is an orally active, potent JAK inhibitor[1][2]. |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target |
|
||||||||||||
In Vitro |
Ruxolitinib (S enantiomer) (S-Ruxolitinib; 10 μM; 12 hours) suppresses IFNβ-induced expression of ISG, IFIT, and IFITM[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCR[1]
|
||||||||||||
In Vivo |
Ruxolitinib (S enantiomer) (S-Ruxolitinib; 30 mg/kg; Oral gavage; twice per day separated 10-12 h for 8 weeks) reduces haematopoietic cell expansion in MPN[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||
Peso molecular |
306.37 |
||||||||||||
Fòrmula |
C17H18N6 |
||||||||||||
No. CAS |
941685-37-6 |
||||||||||||
Appearance |
Solid |
||||||||||||
Color |
White to off-white |
||||||||||||
SMILES |
N#CC[C@@H](C1CCCC1)N2N=CC(C3=NC=NC4=C3C=CN4)=C2 |
||||||||||||
Envío | Room temperature in continental US; may vary elsewhere. |
||||||||||||
Almacenamiento |
|
||||||||||||
Solvente y solubilidad |
In Vitro:
DMSO : ≥ 100 mg/mL (326.40 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) 1M HCl : 50 mg/mL (163.20 mM; ultrasonic and adjust pH to 1 with HCl) *"≥" means soluble, but saturation unknown. Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol) Concentration (start) × Volume (start) = Concentration (final) × Volume (final) This equation is commonly abbreviated as: C1V1 = C2V2 In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage mg/kgAnimal weight Dosing volume Number of animals Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO
+
%
+
%
Tween-80
+
%
Saline
The co-solvents required include: DMSO,
. All of co-solvents are available by MedChemExpress (MCE).
, Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
|
||||||||||||
Pureza y Documentación |
Purity: 99.94% |
||||||||||||
Referencias |
|
Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
---|
1M HCl / DMSO | 1 mM | 3.2640 mL | 16.3201 mL | 32.6403 mL | 81.6007 mL |
5 mM | 0.6528 mL | 3.2640 mL | 6.5281 mL | 16.3201 mL | |
10 mM | 0.3264 mL | 1.6320 mL | 3.2640 mL | 8.1601 mL | |
15 mM | 0.2176 mL | 1.0880 mL | 2.1760 mL | 5.4400 mL | |
20 mM | 0.1632 mL | 0.8160 mL | 1.6320 mL | 4.0800 mL | |
25 mM | 0.1306 mL | 0.6528 mL | 1.3056 mL | 3.2640 mL | |
30 mM | 0.1088 mL | 0.5440 mL | 1.0880 mL | 2.7200 mL | |
40 mM | 0.0816 mL | 0.4080 mL | 0.8160 mL | 2.0400 mL | |
50 mM | 0.0653 mL | 0.3264 mL | 0.6528 mL | 1.6320 mL | |
60 mM | 0.0544 mL | 0.2720 mL | 0.5440 mL | 1.3600 mL | |
80 mM | 0.0408 mL | 0.2040 mL | 0.4080 mL | 1.0200 mL | |
100 mM | 0.0326 mL | 0.1632 mL | 0.3264 mL | 0.8160 mL |
Ruxolitinib (S enantiomer) Related Classifications
- Epigenetics Stem Cell/Wnt Protein Tyrosine Kinase/RTK JAK/STAT Signaling
- JAK